Alex M. Fichtenholtz

发表

Predicting Significance of Unknown Variants in Glial Tumors Through Sub-Class Enrichment

Eric K. Neumann, Alex M. Fichtenholtz, Nicholas D. Camarda, 2016, PSB.

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

Alex M. Fichtenholtz, James X. Sun, M. Rubin, 2013, Nature Biotechnology.

Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery.

Alex M. Fichtenholtz, Miqin Zhang, Conroy Sun, 2006, Small.

LYMPHOID NEOPLASIA Integrated genomic DNA/RNA pro ﬁ ling of hematologic malignancies in the clinical setting

Alex M. Fichtenholtz, S. Armstrong, P. Stephens, 2016 .

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Mark Rosenzweig, Joel Greshock, Doron Lipson, 2015, Cancer discovery.

Abstract 1118: Activation of MET via diverse exon 14 skipping mutations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors

Alex M. Fichtenholtz, P. Stephens, R. Yelensky, 2015 .

Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.

Alex M. Fichtenholtz, S. Armstrong, P. Stephens, 2016, Blood.

Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay

Alex M. Fichtenholtz, S. Armstrong, P. Stephens, 2013 .